Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE …
Y Wang, C Wang, Z Chen, J Zhang, Z Liu, B Jin… - Thrombosis …, 2013 - Springer
Abstract Background The worldwide EINSTEIN DVT and EINSTEIN PE studies randomized
8282 patients with acute symptomatic deep-vein thrombosis (DVT) and/or pulmonary …
8282 patients with acute symptomatic deep-vein thrombosis (DVT) and/or pulmonary …
Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism–the J-EINSTEIN DVT and PE program
N Yamada, A Hirayama, H Maeda, S Sakagami… - Thrombosis journal, 2015 - Springer
Abstract Background The global EINSTEIN DVT and PE studies compared rivaroxaban (15
mg twice daily for 3 weeks followed by 20 mg once daily) with enoxaparin/vitamin K …
mg twice daily for 3 weeks followed by 20 mg once daily) with enoxaparin/vitamin K …
[HTML][HTML] Oral rivaroxaban for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN DVT and EINSTEIN PE studies
HR Buller - Blood, 2012 - Elsevier
Abstract Abstract 20 Harry R. Büller, MD, PhD on behalf of the EINSTEIN Investigators.
Background The EINSTEIN DVT and EINSTEIN PE studies showed that a fixed-dose …
Background The EINSTEIN DVT and EINSTEIN PE studies showed that a fixed-dose …
Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism
B van Bellen, L Bamber… - … medical research and …, 2014 - Taylor & Francis
Abstract Objective: The phase III EINSTEIN DVT and EINSTEIN PE trials demonstrated the
potential of oral rivaroxaban for the treatment of deep vein thrombosis (DVT) and pulmonary …
potential of oral rivaroxaban for the treatment of deep vein thrombosis (DVT) and pulmonary …
XALIA: rationale and design of a non-interventional study of rivaroxaban compared with standard therapy for initial and long-term anticoagulation in deep vein …
Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary
embolism, poses a substantial clinical risk, and the incidence of these thrombotic-related …
embolism, poses a substantial clinical risk, and the incidence of these thrombotic-related …
A multicenter prospective observational cohort study to investigate the effectiveness and safety of rivaroxaban in Japanese venous thromboembolism patients (the J' …
Y Okumura, I Fukuda, M Nakamura, N Yamada… - Circulation …, 2020 - jstage.jst.go.jp
Background: There is insufficient real-world data on the current status of Japanese patients
with venous thromboembolism (VTE) or its treatment and prevention with rivaroxaban …
with venous thromboembolism (VTE) or its treatment and prevention with rivaroxaban …
Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized …
MH Prins, AWA Lensing, R Bauersachs, B Van Bellen… - Thrombosis journal, 2013 - Springer
Background Standard treatment for venous thromboembolism (VTE) consists of a heparin
combined with vitamin K antagonists. Direct oral anticoagulants have been investigated for …
combined with vitamin K antagonists. Direct oral anticoagulants have been investigated for …
[HTML][HTML] XALIA-LEA: An observational study of venous thromboembolism treatment with rivaroxaban and standard anticoagulation in the Asia-Pacific, Eastern Europe …
R Kreutz, LG Mantovani, S Haas, D Monje… - Thrombosis research, 2019 - Elsevier
Introduction The prospective, non-interventional XALIA study investigated the safety and
effectiveness of rivaroxaban and standard anticoagulation for the treatment of deep vein …
effectiveness of rivaroxaban and standard anticoagulation for the treatment of deep vein …
Rivaroxaban: a review of its use in the treatment of deep vein thrombosis or pulmonary embolism and the prevention of recurrent venous thromboembolism
CB Burness, CM Perry - Drugs, 2014 - Springer
Rivaroxaban (Xarelto®), an oral direct factor Xa inhibitor, is approved for the initial treatment
of deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as the prevention of …
of deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as the prevention of …
Shortened length of hospital stay with rivaroxaban in patients with symptomatic venous thromboembolism in Japan: the J-EINSTEIN pulmonary embolism and deep …
H Matsuo, M Prins, AWA Lensing… - … medical research and …, 2015 - Taylor & Francis
Abstract Background: In Japan, the standard of care for the treatment of pulmonary
embolism (PE) and/or deep vein thrombosis (DVT) consists of intravenous unfractionated …
embolism (PE) and/or deep vein thrombosis (DVT) consists of intravenous unfractionated …
相关搜索
- pulmonary embolism vein thrombosis
- oral rivaroxaban einstein dvt
- pooled analysis einstein dvt
- standard therapy vein thrombosis
- oral rivaroxaban pooled analysis
- chinese patients einstein dvt
- pulmonary embolism einstein dvt
- pulmonary embolism rivaroxaban in patients
- subgroup analysis chinese patients
- analysis of patients vein thrombosis
- pulmonary embolism subgroup analysis
- thromboembolism patients safety of rivaroxaban
- standard therapy einstein dvt
- standard therapy analysis of patients
- shortened length rivaroxaban in patients
- hospital stay rivaroxaban in patients